Suppr超能文献

血管扩张性休克成年危重症患者的最佳目标血压:一项系统评价与荟萃分析。

Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis.

作者信息

Yoshimoto Hidero, Fukui Satoshi, Higashio Koki, Endo Akira, Takasu Akira, Yamakawa Kazuma

机构信息

Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.

Department of Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.

出版信息

Front Physiol. 2022 Aug 16;13:962670. doi: 10.3389/fphys.2022.962670. eCollection 2022.

Abstract

While the Surviving Sepsis Campaign guidelines recommend an initial target value of 65 mmHg as the mean arterial pressure (MAP) in patients with septic shock, the optimal MAP target for improving outcomes remains controversial. We performed a meta-analysis to evaluate the optimal MAP for patients with vasodilatory shock, which included three randomized controlled trials that recruited 3,357 patients. Between the lower (60-70 mmHg) and higher (>70 mmHg) MAP target groups, there was no significant difference in all-cause mortality (risk ratio [RR], 1.06; 95% confidence intervals [CI], 0.98-1.16) which was similar in patients with chronic hypertension (RR, 1.10; 95% CI, 0.98-1.24) and patients aged ≥65 years (RR, 1.10; 95% CI, 0.99-1.21). No significant difference in adverse events was observed between the different MAP groups (RR, 1.04; 95% CI, 0.87-1.24); however, supraventricular arrhythmia was significantly higher in the higher MAP group (RR, 1.73; 95% CI, 1.15-2.60). Renal replacement therapy was reduced in the higher MAP group of patients with chronic hypertension (RR, 0.83; 95% CI, 0.71-0.98). Though the higher MAP control did not improve the mortality rate, it may be beneficial in reducing renal replacement therapy in patients with chronic hypertension. UMIN Clinical Trials Registry, identifier UMIN000042624.

摘要

虽然拯救脓毒症运动指南建议将脓毒性休克患者的平均动脉压(MAP)初始目标值设定为65 mmHg,但改善预后的最佳MAP目标仍存在争议。我们进行了一项荟萃分析,以评估血管舒张性休克患者的最佳MAP,该分析纳入了三项随机对照试验,共招募了3357例患者。在较低MAP目标组(60 - 70 mmHg)和较高MAP目标组(>70 mmHg)之间,全因死亡率无显著差异(风险比[RR],1.06;95%置信区间[CI],0.98 - 1.16),慢性高血压患者(RR,1.10;95% CI,0.98 - 1.24)和年龄≥65岁的患者(RR,1.10;95% CI,0.99 - 1.21)中也是如此。不同MAP组之间不良事件无显著差异(RR,1.04;95% CI,0.87 - 1.24);然而,较高MAP组的室上性心律失常显著更高(RR,1.73;95% CI,1.15 - 2.60)。慢性高血压患者的较高MAP组中肾脏替代治疗减少(RR,0.83;95% CI,0.71 - 0.98)。虽然较高的MAP控制并未提高死亡率,但可能有利于减少慢性高血压患者的肾脏替代治疗。UMIN临床试验注册中心,标识符UMIN000042624。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e68/9424848/c1d455e05a12/fphys-13-962670-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验